Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter C Butler

Showing results (1-10 of 104) with videos related to

Pageof 11
Sort By:
The New England Journal of Medicine|March 11, 2021
Supplying Insulin while Evading ImmunityPeter C Butler
Diabetes|October 31, 2009
Insulin glargine controversy: a tribute to the editorial team at DiabetologiaPeter C Butler
JAMA Internal Medicine|August 2, 2016
Glucagon-like Peptide 1 Drugs as Second-line Therapy for Type 2 DiabetesPeter C Butler
Diabetes|November 24, 2011
Farewell statement from Dr. Peter Butler as outgoing editor in chief of diabetesPeter C Butler
JAMA Internal Medicine|March 7, 2013
Glucagonlike Peptide 1-based drugs and pancreatitis: clarity at last, but what about pancreatic cancer?Belinda Gier, Peter C Butler
Cell Metabolism|August 8, 2014
Insulin-degrading enzyme inhibition, a novel therapy for type 2 diabetes?Safia Costes, Peter C Butler
Diabetes|June 29, 2006
Beta-cell deficit due to increased apoptosis in the human islet amyloid polypeptide transgenic (HIP) rat recapitulates the metabolic defects present in type 2 diabetesAleksey V Matveyenko, Peter C Butler
Diabetes|June 28, 2003
Replication increases beta-cell vulnerability to human islet amyloid polypeptide-induced apoptosisRobert A Ritzel, Peter C Butler
The Journal of Clinical Investigation|February 1, 2022
Reversing type 1 diabetes with stem cell-derived islets: a step closer to the dream?Peter C Butler, Edwin Am Gale
ILAR Journal|June 29, 2006
Islet amyloid polypeptide (IAPP) transgenic rodents as models for type 2 diabetesAleksey V Matveyenko, Peter C Butler
Pageof 11

Showing results (1-10 of 104) with videos related to

Sort By:
Pageof 11
The New England Journal of Medicine|March 11, 2021
Supplying Insulin while Evading ImmunityPeter C Butler
Diabetes|October 31, 2009
Insulin glargine controversy: a tribute to the editorial team at DiabetologiaPeter C Butler
JAMA Internal Medicine|August 2, 2016
Glucagon-like Peptide 1 Drugs as Second-line Therapy for Type 2 DiabetesPeter C Butler
Diabetes|November 24, 2011
Farewell statement from Dr. Peter Butler as outgoing editor in chief of diabetesPeter C Butler
JAMA Internal Medicine|March 7, 2013
Glucagonlike Peptide 1-based drugs and pancreatitis: clarity at last, but what about pancreatic cancer?Belinda Gier, Peter C Butler
Cell Metabolism|August 8, 2014
Insulin-degrading enzyme inhibition, a novel therapy for type 2 diabetes?Safia Costes, Peter C Butler
Diabetes|June 29, 2006
Beta-cell deficit due to increased apoptosis in the human islet amyloid polypeptide transgenic (HIP) rat recapitulates the metabolic defects present in type 2 diabetesAleksey V Matveyenko, Peter C Butler
Diabetes|June 28, 2003
Replication increases beta-cell vulnerability to human islet amyloid polypeptide-induced apoptosisRobert A Ritzel, Peter C Butler
The Journal of Clinical Investigation|February 1, 2022
Reversing type 1 diabetes with stem cell-derived islets: a step closer to the dream?Peter C Butler, Edwin Am Gale
ILAR Journal|June 29, 2006
Islet amyloid polypeptide (IAPP) transgenic rodents as models for type 2 diabetesAleksey V Matveyenko, Peter C Butler
Pageof 11